Shares of ThermoGenesis Holdings THMO decreased in after-market trading after the company reported Q1 results.
Earnings per share were up 85.59% year over year to ($0.16), which missed the estimate of ($0.13).
Revenue of $1,517,000 decreased by 52.59% from the same period last year, which missed the estimate of $2,660,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 13, 2021
Time: 04:30 PM
52-week high: $11.70
52-week low: $1.92
Price action over last quarter: down 15.19%
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.